High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients

Borsi, E; Mazzocchetti, G; Dico, AF; Vigliotta, I; Martello, M; Poletti, A; Solli, V; Armuzzi, S; Taurisano, B; Kanapari, A; Pistis, I; Zamagni, E; Tacchetti, P; Pantani, L; Mancuso, K; Rocchi, S; Rizzello, I; Cavo, M; Terragna, C

Borsi, E; Terragna, C (通讯作者)，Univ Bologna, IRCCS Azienda Osped, Ist Ematol Seragnoli, Bologna, Italy.

CLINICAL AND EXPERIMENTAL MEDICINE, 2023; ():

Abstract

In recent years, the immunoderivative (IMiD) agents have been extensively used for the treatment of multiple myeloma (MM). IMiDs and their newer deriv......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索